Tohoku Univ. Technology : Drugs for Stress urinary incontinence: T16-194
Novel mechanisms targeting luteinizing hormone
Stress urinary incontinence (SUI) is a disorder that affects young and old people and significantly reduces their quality of life. It has been thought to be caused by a decrease in estrogen, but estrogen replacement therapy has not been sufficiently effective, and there is currently no effective oral treatment that is the first choice, so the development of new therapeutic agents is expected. Because of the poor prognosis of SUI in patients with high serum luteinizing hormone (LH) levels before radical prostatectomy, the inventors considered LH to play an important role in urinary function. To test this hypothesis, they found that the gonadotropin-releasing hormone GnRH antagonists degarellirex or cetrorellix suppressed LH and improved urethral pressure in model rats that reproduced the menopausal state by removing the bilateral ovaries and had elevated LH. The results showed that there is a relationship between SUI and elevated LH, and that GnRH antagonists that suppress LH may be novel therapeutic agents.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
![[Research Material] Global Market for Treatment of Acquired Cystic Kidney Disease](https://image.mono.ipros.com/public/product/image/2ea/2001460387/IPROS97737285997563145397.jpeg?w=280&h=280)
![[Research Material] Global Market for Women's Health Treatments](https://image.mono.ipros.com/public/product/image/bf2/2001456707/IPROS28358403231524289686.jpeg?w=280&h=280)
![[Research Material] Global Market for the Treatment of Glioblastoma Multiforme (GBM)](https://image.mono.ipros.com/public/product/image/8c0/2001460125/IPROS57282443678317485614.jpeg?w=280&h=280)
![[Research Material] Global Market for Zika Virus Infection Treatment Drugs](https://image.mono.ipros.com/public/product/image/ab6/2001456888/IPROS98310603290033560788.jpeg?w=280&h=280)
![[Leveling Correction] Leveling correction of concrete floors "Teratec Method"](https://image.mono.ipros.com/public/product/image/d08/1267539002/IPROS70063422645318547243.jpeg?w=280&h=280)
